COMMUNIQUÉS West-GlobeNewswire

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
06/11/2025
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to [...]
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
06/11/2025
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori [...]
WeightWatchers Announces Third Quarter 2025 Results
06/11/2025
End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net [...]
Pow.Bio, Bühler, and ATV Technologies Announce Major Advancement in Continuous Biomanufacturing with 3,000-Liter Scale Success
06/11/2025
ALAMEDA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pow.Bio, the pioneer in continuous biomanufacturing, Bühler Group, the global solutions provider for food, feed, and advanced materials, and ATV Technologies, the [...]
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
06/11/2025
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase [...]
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
06/11/2025
- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of [...]
Teleflex Announces Quarterly Dividend
06/11/2025
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The [...]
Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook
06/11/2025
Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year period Third Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year period Adjusted EBITDA for Q3 [...]
Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook
06/11/2025
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025. Third quarter financial summary GAAP [...]
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
06/11/2025
-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome [...]
CARBIOS and Wankai New Materials, a subsidiary of Zhink Group, are committed to the large-scale deployment of CARBIOS’ PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.
06/11/2025
The two Groups have reached a binding agreement on the main principles of their collaboration, with a view to deploying a capacity of one million tonnes in the long term, Starting with the construction of a plant in [...]
CARBIOS et Wankai New Materials, filiale du Groupe Zhink, s’engagent pour le déploiement à très grande échelle de la technologie de biorecyclage du PET de CARBIOS en Asie, avec comme première étape la construction d’une usine en Chine.
06/11/2025
Les deux Groupes se sont accordés de manière engageante sur les grands principes de leur collaboration, en vue de déployer une capacité de 1 million de tonnes à long terme, Débutant par la construction en Chine d’une [...]
8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.
06/11/2025
Ester Baiget, President & CEO: ” I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all [...]
Interim Report Q3 2025: Solid quarter with 1% organic growth, 11% EBITA margin and DKK 410 million cash flow
06/11/2025
Highlights The Hearing division delivered 7% organic revenue growth driven by the continued strong performance of ReSound Vivia, enabling broad-based market share gains. The divisional profit margin ended at 34%, driven [...]
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
06/11/2025
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024 RUCONEST® third quarter revenu e increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting [...]
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of Bv100 in China
06/11/2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) -- First healthy volunteer dosed with BV100 in China in mandatory Phase 1 trial Inclusion of Chinese clinical sites by H2 [...]
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
06/11/2025
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines [...]
BillionToOne Announces Pricing of Upsized Initial Public Offering
06/11/2025
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced [...]
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
06/11/2025
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]

Pages